Literature DB >> 1399729

The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985).

M Roach1, J Krall, J W Keller, C A Perez, W T Sause, R L Doggett, M Rotman, H Russ, M V Pilepich, S O Asbell.   

Abstract

A number of studies have identified race as a prognostic factor for survival from prostate cancer. To evaluate the prognostic significance of race in a controlled setting, we evaluated 1294 patients treated on three prospective randomized trials conducted by the Radiation Therapy Oncology Group between 1976 to 1985. One-hundred and twenty (9%) of the patients were coded as black, while 1077 (83%) of the patients were coded as white. Protocol 7506 included 607 patients with clinical Stage T3-T4Nx or T1b-T2N1-2. Protocol 7706 included 484 patients with clinical Stage T1b or T2 who were node negative. Protocol 8307 included 203 Stage T2b-T4 patients with no lymph node involvement beyond the pelvis. Univariate and multivariate analyses were used to assess the possible independent significance of race and other prognostic factors, including Gleason score, serum acid phosphatase, nodal status, and hormonal status. Protocols 7706 and 8307 revealed that race was not of prognostic significance for disease-free or overall survival by either univariate or multivariate analysis. Univariate analysis of Protocol 7506 revealed that the median survival for blacks was somewhat shorter (5.4 years vs. 7.1 years, p = 0.02). This difference persisted after a multivariate analysis. A higher percentage of blacks treated on 7506 had an abnormally elevated serum acid phosphatase compared to whites (p = 0.006), and the time to distant failure tended to be shorter (p = 0.07). These findings suggest that blacks treated on 7506 may have had more extensive disease at presentation. Based on these prospective randomized trials, it is most likely that the lower survival noted for black Americans with prostate cancer reflects the tendency for blacks to present with more advanced disease. Differences in access to care, the quality of care received, and the impact of co-morbid conditions may explain the lower survival reported for black Americans elsewhere in the literature.

Entities:  

Mesh:

Year:  1992        PMID: 1399729     DOI: 10.1016/0360-3016(92)91058-u

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

Review 1.  Is race an independent prognostic factor for survival from prostate cancer?

Authors:  M Roach
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

2.  Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection.

Authors:  J W Moul
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

3.  African-american race is a predictor of seminal vesicle invasion after radical prostatectomy.

Authors:  Kosj Yamoah; Amy Walker; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Adam P Dicker; Timothy R Rebbeck; Priti Lal
Journal:  Clin Genitourin Cancer       Date:  2014-10-25       Impact factor: 2.872

4.  Prostate cancer: epidemiology and screening.

Authors:  M K Brawer; E D Crawford; J Fowler; M S Lucia; F H Schröeder
Journal:  Rev Urol       Date:  2000

5.  Participation in clinical trials: is it state-of-the-art treatment for African Americans and other people of color?

Authors:  C R Thomas; H A Pinto; M Roach; C B Vaughn
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

6.  Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer.

Authors:  Charles J Rosser; Deborah A Kuban; Sang-Joon Lee; Lawrence B Levy; Curtis Pettaway; Ashish M Kamat; Ramsey Chichakli; Andrew Lee; Rex M Cheung; Ricardo Sanchez-Ortiz; Louis L Pisters
Journal:  J Natl Med Assoc       Date:  2004-07       Impact factor: 1.798

7.  Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy.

Authors:  Curtis Bryant; Bradford S Hoppe; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Tamara L Smith; Christopher G Morris; Christopher R Williams; Zhong Su; Zuofeng Li; Nancy P Mendenhall
Journal:  Int J Part Ther       Date:  2017-07-11

8.  Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?

Authors:  Shaakir Hasan; Daniel Gorovets; Eric Lehrer; Stanislav Lazarev; Robert H Press; Madhur Garg; Keyur J Mehta; Arpit M Chhabra; J Isabelle Choi; Charles B Simone
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-25

9.  Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes.

Authors:  Kosj Yamoah; Kwamena Beecham; Sarah E Hegarty; Terry Hyslop; Timothy Showalter; Joel Yarney
Journal:  BMC Cancer       Date:  2013-01-16       Impact factor: 4.430

Review 10.  Screening for prostate cancer in African Americans.

Authors:  J W Moul
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.